Fragment-informed SAR: rational construction of quinoline derivatives as dual AChE/BChE inhibitors
- Bioorg Chem. 2025 Aug:163:108747. doi: 10.1016/j.bioorg.2025.108747.
- 1. Precision Pharmacy & Drug Development Center, Department of Pharmacy, Tangdu Hospital, Air Force Medical University, Xi'an 710038, China; Department of Medicinal Chemistry, School of Pharmacy, Air Force Medical University, Xi'an 710032, China.
- 2. Department of Pharmacy, The 969th Hospital of the joint logistics support force of PLA, Hohhot 010051, China.
- 3. Department of Medicinal Chemistry, School of Pharmacy, Air Force Medical University, Xi'an 710032, China.
- 4. Precision Pharmacy & Drug Development Center, Department of Pharmacy, Tangdu Hospital, Air Force Medical University, Xi'an 710038, China.
- 5. Precision Pharmacy & Drug Development Center, Department of Pharmacy, Tangdu Hospital, Air Force Medical University, Xi'an 710038, China; Institute of Medical Research, Northwestern Polytechnical University, Xi'an 710072, China.
- 6. Department of Medicinal Chemistry, School of Pharmacy, Air Force Medical University, Xi'an 710032, China. Electronic address: [email protected].
- 7. Precision Pharmacy & Drug Development Center, Department of Pharmacy, Tangdu Hospital, Air Force Medical University, Xi'an 710038, China; Institute of Medical Research, Northwestern Polytechnical University, Xi'an 710072, China. Electronic address: [email protected].
- 8. Precision Pharmacy & Drug Development Center, Department of Pharmacy, Tangdu Hospital, Air Force Medical University, Xi'an 710038, China; Department of Medicinal Chemistry, School of Pharmacy, Air Force Medical University, Xi'an 710032, China. Electronic address: [email protected].
This study introduces a Fragment-Informed Structure-Activity Relationship (FI-SAR) paradigm for developing cholinesterase inhibitors through strategic coupling of amino-functionalized fragments with quinoline scaffolds. A library of 105 conjugates was synthesized and comprehensively assessed to delineate fragment-to-conjugate activity transfer. Quantitative analysis revealed a positive correlation between fragment potency and conjugate inhibitory activity, with phenolic Mannich base derivatives showing the strongest interdependence. Notably, representative conjugate L4R1-3 achieved sub-nanomolar AChE inhibition (IC₅₀ = 4.6 nM), outperforming clinical references such as donepezil. Furthermore, dual-target inhibitors were constructed (e.g., L1-3, AChE/BChE IC₅₀ = 8.1/0.58 μM) by using FI-SAR strategy. Molecular simulations confirmed stable binding modes of high-activity conjugates within the AChE/BChE active site. This work establishes a streamlined FI-SAR framework, emphasizing that strategic fusion of privileged pharmacophores (e.g., phenolic Mannich Bases) with versatile scaffolds like quinoline can accelerate multi-target drug discovery, suggesting broader applicability to enzyme-driven diseases.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Cholinesterase (ChE)Research Areas: Neurological Disease